June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Relationship between foveal development and persistent avascular retina
Author Affiliations & Notes
  • Susan Ostmo
    Ophthalmology, Oregon Health & Science University, Portland, Oregon, United States
  • Thiago Barros de Oliveira
    Ophthalmology, Centro Universitario Christus, Fortaleza, Ceará, Brazil
    Ophthalmology, Instituto Cearense de Oftalmologia, Fortaleza, Ceará, Brazil
  • Aaron S Coyner
    Ophthalmology, Oregon Health & Science University, Portland, Oregon, United States
  • Rebekah H Gensure
    Ophthalmology, The Eye Institute of Utah, Salt Lake City, Utah, United States
  • Brittni Scruggs
    Ophthalmology, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States
  • Jamie Anderson
    Ophthalmology, Oregon Health & Science University, Portland, Oregon, United States
  • Darius M Moshfeghi
    Ophthalmology, Stanford Medicine, Stanford, California, United States
  • J. Peter Campbell
    Ophthalmology, Oregon Health & Science University, Portland, Oregon, United States
  • Footnotes
    Commercial Relationships   Susan Ostmo None; Thiago Barros de Oliveira None; Aaron Coyner Boston AI Lab, Code R (Recipient); Rebekah Gensure None; Brittni Scruggs None; Jamie Anderson None; Darius Moshfeghi Akceso Advisors AG, Bayer, Congruence Medical Solutions, Ocular Surgery News, Praxis Inc, Retina Technologies LLC, Retina Today/Pentavision, Regeneron Pharmaceuticals, and SLACK, Akebia, Alcon, Allegro, Iconic Therapeutics, Irenix, Novartis, Pykus, and Visunex; having equity in DSentz, Grand Legend Technology, Linc, Pr3vent, Promisight, Pykus, VersI, and Visunex; serving on the board of directors for DSentz, Linc, Pr3vent, and Promisight, Code C (Consultant/Contractor), Akebia Therapeutics, Bayer, Novartis, Regeneron Pharmaceuticals, and the Shapiro Law Group, Code F (Financial Support), Aldeyra Therapeutics, Apellis, Genentech, the National Institutes of Health, and Regeneron Pharmaceuticals, Code R (Recipient), CMEOutfitters.com, Cole Eye Institute, Northwell Health, Prime Medical Education, Regeneron Pharmaceuticals, University of Miami, Vindico, and Visunex, Code S (non-remunerative); J. Peter Campbell Boston AI Lab, Code C (Consultant/Contractor), Genentech, Code F (Financial Support), Siloam Vision, Code O (Owner), Boston AI Lab, Code R (Recipient)
  • Footnotes
    Support  R01EY19474, R01 EY031331, R21 EY031883, and P30 EY10572 from the National Institutes of Health (Bethesda, MD), an investigator-initiated grant from Genentech (San Francisco, CA), and by unrestricted departmental funding and a Career Development Award (JPC) from Research to Prevent Blindness (New York, NY).
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4928. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Susan Ostmo, Thiago Barros de Oliveira, Aaron S Coyner, Rebekah H Gensure, Brittni Scruggs, Jamie Anderson, Darius M Moshfeghi, J. Peter Campbell; Relationship between foveal development and persistent avascular retina. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4928.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Persistent avascular retina (PAR) is recognized as a long-term sequela of retinopathy of prematurity (ROP), and may predispose patients to late vitreoretinal complications, such as retinal detachment. It can be diagnosed in childhood with oral ultra-widefield fluorescein angiography (UWFFA) but this is not widely available or utilized. The purpose of this study was to evaluate the relationship between optical coherence tomography (OCT) macular parameters and the presence of PAR.

Methods : We recruited children aged 4–8 years from the i-ROP cohort study for long-term follow-up examination with both UWFFA and OCT angiography (OCTA). Exclusion criteria were UWFFA without clear visualization of zone 2 or low-quality OCTA. PAR was assessed by two masked graders. We compared birthweight (BW) and gestational age (GA) using a two-sample t-test and Mann-Whitney test, respectively, and OCT/A features between those with and without PAR using generalized estimating equations (GEE). Multiple comparisons were addressed using Benjamini & Hochberg p-value correction.

Results : 36 eyes of 21 patients met the study criteria. The Table summarizes the findings in both groups. We found higher central retina thickness (CRT), higher foveal vessel density (smaller FAZ), and lower quadrant vessel densities in eyes with PAR. The Figure shows the relationship between CRT and the probability of PAR.

Conclusions : It is well known that a history of premature birth is associated with less developed foveal architecture (thicker CRT). In this study, we found an association between CRT and the presence of PAR. In the future, OCT may help identify those patients who would most benefit from an UWFFA to identify clinically significant PAR.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.




This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.